Nanox Provides Business Update and Furnishes Certain Preliminary Unaudited Financial Data for Third Quarter Ended September 30, 2026
Management expects available funds will not cover current operating plans for at least one year, creating a need for additional funding.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nanox (NNOX) released preliminary third-quarter 2026 financial data and warned that funding constraints raise substantial doubt about continuing operations. Estimated cash, cash equivalents and deposits were approximately $26.0 million at September 30, versus $60.0 million at December 31, 2025. Management expects these funds will not support current operating plans for at least one year from October 16, 2026.
Preliminary quarterly AI and software revenue was $1.0 million, versus $0.1 million a year earlier, mainly reflecting the consolidation of Vaso Healthcare IT. Imaging systems and OEM services revenue was approximately $0.3 million, versus $0.2 million; teleradiology revenue was approximately $3.1 million, versus $3.1 million. Nanox.AI signed a distribution agreement with Technologic to commercialize its Bone Solution in Italy. Final quarterly results may differ materially from these preliminary, unaudited figures.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointAI and software revenue reached $1.0 million in preliminary Q3 2026 data, versus $0.1 million a year earlier.
- Moderate pointImaging systems and OEM services revenue rose to approximately $0.3 million from $0.2 million a year earlier.
- Minor pointTechnologic distribution agreement provides for commercialization of Nanox.AI’s Bone Solution in Italy.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Substantial going-concern doubt reflects management’s expectation that funds cannot support current plans for at least one year.
- Moderate pointCash, cash equivalents and deposits are expected at approximately $26.0 million September 30, versus $60.0 million December 31, 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Failure to raise needed funds could force development or commercialization cuts, delays, elimination, or granting product rights.
- Minor point. Forward-looking: it has not happened yet and may not happen.Preliminary, unaudited Q3 2026 figures remain subject to review and adjustments; final results may differ materially.
News Explained
Nanox says that if it cannot raise additional funds when needed, it may have to delay, reduce or eliminate product development or future commercialization, or grant others rights to develop and market products it would otherwise prefer to develop and market itself.
Details
Market move: NNOX -3.93% vs previous close. 3Q26 preliminary financial data
On Oct 16, the day this news came out, the latest delayed price for NNOX is 3.93% below the previous close. Our momentum scanner has recorded 11 alerts for this stock so far that day. The latest delayed price is $0.44.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- AI and software solutions revenue
- $1.0 million vs. $0.1 million
- Third quarter 2026 vs. comparable period in 2025
- Imaging systems and OEM services revenue
- Approximately $0.3 million vs. $0.2 million
- Third quarter 2026 vs. comparable period in 2025
- Teleradiology services revenue
- Approximately $3.1 million vs. $3.1 million
- Third quarter 2026 vs. comparable period in 2025
- Cash, cash equivalents and deposits
- Approximately $26.0 million vs. $60.0 million
- September 30, 2026 vs. December 31, 2025
- Funding sufficiency
- Not sufficient for at least one year
- Management's assessment as of September 30, 2026, under current operating plans
Historical Context
-
Q2 cash was $31.4 million; the company also raised $8.5 million post-quarter.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
teleradiology medical
going concern financial
tomosynthesis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PETACH TIKVA, Israel, Oct. 16, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today provided a brief business update and furnished certain preliminary unaudited financial data for the third quarter ended September 30, 2026. The preliminary figures are estimates based on currently available information, are preliminary and unaudited, and are subject to change upon completion of the Company’s financial close process, final adjustments, management review and other internal procedures, and review by its independent auditors. The Company’s final reported unaudited financial results for the third quarter of 2026 may differ materially from the preliminary figures and will be reported in a subsequent press release at a later date.
Business Update
Nanox.AI: Nanox AI enters into a distribution agreement with Technologic s.r.l., an Affiliate of Tecnologie Avanzate, to commercialize Nanox.AI’s Bone Solution in Italy. Collaboration leverages Tecnologie Avanzate’s experience, established healthcare industry relationships, and expertise in the Italian market.
TIME Best Inventions Recognition: Nanox selected as one of TIME’s Best Inventions of 2026 for its Nanox.ARC X. Nanox.ARC X recognized among the “world’s most groundbreaking innovations” and for its approach to making advanced medical imaging more accessible.
Preliminary Financial Data for the Three Months Ended September 30, 2026
Cautionary Note Regarding Preliminary Financial Data
The preliminary financial data set forth below represents the Company’s current estimates based on information available as of the date of this press release. These estimates are preliminary and unaudited, have been prepared by and are the responsibility of the Company’s management, and are subject to the completion of the Company’s financial closing procedures, final adjustments, management review and other internal review procedures, and other developments that may arise between now and the time the financial results are finalized.
In addition, the Company’s independent registered public accounting firm has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial results. Accordingly, it does not express an opinion or any other form of assurance with respect thereto.
Preliminary Revenue Data
On a preliminary unaudited basis, the Company expects its revenue to be approximately
The Company’s revenue from teleradiology services for the Reported Period was approximately
During the Reported Period, the Company generated revenue through the sale and deployment of its imaging systems and OEM services which amounted to approximately
The Company’s revenue from its AI and software solutions for the Reported Period was
Preliminary Balance Sheet Data
On a preliminary unaudited basis, the Company expects its cash, cash equivalents, short-term deposits and long-term restricted deposits to be approximately
The Company expects to continue to incur significant costs related to its ongoing operations. Management expects that the Company’s cash and cash equivalents, and deposits, as of September 30, 2026, are not sufficient to support the Company’s operations under its current operating plans for at least one year from the date of this press release. These factors raise substantial doubt as to the Company’s ability to continue as a going concern. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce or eliminate its product development or future commercialization efforts, or grant rights to develop and market products that it would otherwise prefer to develop and market itself.
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provides access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit https://www.nanox.vision.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements preliminary unaudited revenue, revenue by category, cash, cash equivalents, deposits and restricted deposits; expected future operating costs, liquidity, going concern matters. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) the preliminary and unaudited nature of the financial data included in this press release, the completion of the Company’s financial closing procedures, final adjustments, management review and other internal review procedures and the Company’s ongoing evaluation of potential impairment charges; (ii) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s history of recurring losses and negative cash flows from operating activities, significant future commitments, the uncertainty regarding the adequacy of Nanox’s liquidity to pursue its complete business objectives, substantial doubt regarding its ability to continue as a going concern and its ability to raise additional capital on acceptable terms or at all; (iii) Nanox’s ability to complete development of the Nanox System and successfully demonstrate the feasibility of its technology for commercial applications; (iv) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox’s ability to complete installations, commercially activate sites, support physician outreach and generate anticipated revenue from its imaging systems, AI and software solutions and teleradiology services; (vi) Nanox’s ability to realize the anticipated benefits of acquisitions, distribution arrangements and other commercial agreements, including annual minimum purchase commitments, which may be affected by, among other things, competition, customer adoption, brand recognition, integration risks, the ability of acquired businesses to grow and manage growth profitably and retain key employees; (vii) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (viii) market acceptance of the Nanox System and the proposed pay-per-scan business model; (ix) Nanox’s expectations regarding collaborations with third parties and their potential benefits; (x) Nanox’s ability to conduct business globally; (xi) changes in global, political, economic, business, competitive, market and regulatory forces; (xii) risks related to the current conflict between the United States (and, at times, Israel), on the one hand, and Iran and its proxies, on the other hand, and any adverse impact of that conflict on Israel; and (xiii) risks related to litigation, which may result in significant liability and damage to the Company’s reputation.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in forward-looking statements or from the preliminary unaudited financial data furnished in this press release, please see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 30, 2026, and in subsequent documents filed with, or furnished to, the SEC by Nanox. The reader should not place undue reliance on any forward-looking statements or preliminary unaudited financial data included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements or preliminary unaudited financial data after the date of this press release to conform these statements or data to actual results or to changes in Nanox’s expectations.
Contacts
Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com
Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Nanox warn about its ability to continue as a going concern?
Management expects cash, cash equivalents and deposits at September 30, 2026, will not support current operating plans for at least one year from October 16, 2026. Nanox expects to continue incurring significant operating costs. Without additional funds when needed, it may have to curtail development or commercialization efforts or grant product rights.
What drove Nanox’s preliminary third-quarter 2026 revenue increases?
The AI and software revenue increase mainly reflected consolidation of Vaso Healthcare IT, now Nanox Health IT, while the imaging systems and OEM services increase mainly reflected an additional Nanox.ARC capital-expenditure agreement. AI and software revenue was $1.0 million versus $0.1 million a year earlier; imaging systems and OEM services revenue was approximately $0.3 million versus $0.2 million.